Premium
Neonatal Lupus Erythematosus Related to Maternal Leukocytoclastic Vasculitis
Author(s) -
Borrego Leopoldo,
Rodrìguez Julio,
Soler Elena,
Jiménez Antúnez,
Hernández Buenaventura
Publication year - 1997
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.1997.tb00243.x
Subject(s) - medicine , betamethasone , autoantibody , dermatology , asymptomatic , pregnancy , lupus erythematosus , vasculitis , systemic lupus erythematosus , hydroxychloroquine , heart block , immunology , pediatrics , disease , antibody , covid-19 , biology , infectious disease (medical specialty) , genetics , electrocardiography
Neonatal lupus erythemalosus (NLE) is an autoimmune disease whose major findings are skin lesions and congenital heart block. Affected infants have maternal, transplacentally acquired, autoantibodies to Ro/SSA, La/SSB, or U,‐RNP antigens. Anti‐Ro/SSA is the predominant autoantibody, present in about 95% of cases. Mothers of babies with NLE may be asymptomatic initially or may have Sjógrent syndrome, lupus erythematosus, overlap syndrome or, uncommonly, leukocytoclastic vasculitis. When evaluating a young woman with a cutaneous leucocytoclastic vasculitis, dermatologists should be aware of the possible presence of antibodies related to NLE. If any patient suffering a disorder related to NLE becomes pregnant, testing for autoantibodies and close obstetric prenatal care with fetal echocardiogram is necessary. In cases of fetal bradycardia, treatment with dexamethasone or betamethasone should be considered, as these drugs are accessible to the fetal circulation.